ZEVRA THERAPEUTICS
Zevra Therapeutics is a development-stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. The company’s primary efforts include the development of safer, abuse-resistant opioid pain relievers. Its drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
ZEVRA THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2006-01-01
Address:
Orlando, Florida, United States
Country:
United States
Website Url:
http://www.zevra.com
Total Employee:
11+
Status:
Active
Contact:
888.958.1253
Email Addresses:
[email protected]
Total Funding:
213.75 M USD
Technology used in webpage:
IPv6 MediaElement.js Akamai Hosted
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Revagenix
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-11-20 | Acer Therapeutics | Acer Therapeutics acquired by Zevra Therapeutics | N/A |
Investors List
Perceptive Advisors
Perceptive Advisors investment in Post-IPO Debt - Zevra Therapeutics
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Zevra Therapeutics
Deerfield
Deerfield investment in Debt Financing - Zevra Therapeutics
BP Growth Partners
BP Growth Partners investment in Series B - Zevra Therapeutics
BP Growth Partners
BP Growth Partners investment in Series A - Zevra Therapeutics
Key Employee Changes
Official Site Inspections
http://www.zevra.com Semrush global rank: 2.72 M Semrush visits lastest month: 6.45 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Zevra Therapeutics"
Zevra Therapeutics - A rare approach to therapeutics.
We are a nimble rare disease therapeutics company comprised of expert scientists, patient advocates, development strategists, commercialization specialists, and business development gurus with a proven record of bringing …See details»
Zevra Therapeutics Announces Organizational Changes
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no …See details»
About Us | Zevra Therapeutics
Nov 24, 2024 From 2001 to 2004, Travis Mickle, Ph.D., led the team of scientists who invented Vyvanse ®, a first-of-its-kind prodrug to address issues with the treatments that were then …See details»
Zevra Therapeutics Announces Organizational Changes - Yahoo …
Dec 6, 2024 To further Zevra’s transformation towards becoming a leading rare disease company, Zevra has begun executing its five-year vision to create value for patients and …See details»
Zevra Therapeutics Announces Organizational Changes to …
Zevra Therapeutics announces organizational changes to enhance focus on rare disease therapeutics, consolidating leadership and streamlining operations. Quiver AI Summary Zevra …See details»
Zevra Therapeutics Announces Organizational Changes
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on …See details»
Zevra Therapeutics Announces Organizational Changes
Dec 6, 2024 In a striving industry defined by rapid innovation and harsh competition, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) finds itself at a critical juncture. The company, dedicated …See details»
Zevra Therapeutics’ President and Chief Executive Officer Issues …
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today …See details»
ZEVRA’S APPROACH We are driven by a patient-centric approach, …
Jan 8, 2024 Zevra’s patient advocacy engagement and collaborations in rare disease areas that we support, such as Idiopathic Hypersomnia (IH), Narcolepsy and Niemann-Pick Disease …See details»
Zevra Therapeutics Announces Organizational Changes
Dec 6, 2024 Zevra Therapeutics, Inc. announced organizational changes to enhance its focus on rare disease therapeutics. The company is consolidating its development functions under …See details»
Zevra Therapeutics - Crunchbase Company Profile & Funding
Zevra Therapeutics reported its first quarter 2024 financial results and corporate updates, indicating a mixed performance against analyst estimates. The company is approaching …See details»
Zevra Therapeutics Announces Organizational Changes
Dec 6, 2024 To further Zevra’s transformation towards becoming a leading rare disease company, Zevra has begun executing its five-year vision to create value for patients and …See details»
Zevra Therapeutics - LinkedIn
Vascular Ehlers Danlos Syndrome is a life-threatening #RareDisease, which is why Zevra Therapeutics is committed to bringing a new treatment to the #VEDS community. Through our …See details»
Zevra Therapeutics, Inc. (ZVRA) - Yahoo Finance
See the company profile for Zevra Therapeutics, Inc. (ZVRA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Corporate Presentation - investors.zevra.com
Nov 6, 2024 Certain products may be subject to royalty obligations, details and required disclosures are available in our SEC filings or on our website: www.zevra.com. 1. Data …See details»
Zevra Therapeutics, Inc. (ZVRA) Company Profile & Overview
Apr 16, 2015 Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products …See details»
A drug for fewer than 1,000 patients? Awareness and diagnosis are …
Dec 9, 2024 But Zevra wants to reach more patients and is looking to clinicians to help confirm more diagnoses of the disease. NPC can be mistaken for other conditions such as Gaucher …See details»
Our Approach | Zevra Therapeutics
Like limitless unique and manifold zebra-stripe patterns, our perspective on drug development assumes that there are boundless pathways and infinite possibilities through which difficult …See details»
Zevra Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2023, Zevra’s Quarterly Report …See details»